ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $359,750.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $14.39, for a total transaction of $359,750.00. Following the completion of the transaction, the insider now directly owns 136,380 shares in the company, valued at approximately $1,962,508.20. This represents a 15.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Justin Chakma also recently made the following trade(s):

• On Monday, November 25th, Justin Chakma sold 32,814 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.00, for a total transaction of $459,396.00.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock traded up $0.16 during midday trading on Wednesday, hitting $14.53. The company had a trading volume of 674,132 shares, compared to its average volume of 816,102. The business’s 50 day simple moving average is $14.82 and its two-hundred day simple moving average is $11.97. The stock has a market cap of $1.41 billion, a PE ratio of -28.18 and a beta of 0.90. ARS Pharmaceuticals, Inc. has a 1-year low of $4.65 and a 1-year high of $18.51.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals during the third quarter worth $30,000. Russell Investments Group Ltd. acquired a new stake in ARS Pharmaceuticals during the first quarter worth $60,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in ARS Pharmaceuticals during the second quarter worth $87,000. Finally, J.W. Cole Advisors Inc. boosted its stake in ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after buying an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SPRY. Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ARS Pharmaceuticals has an average rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.